Rhenman Healthcare Equity L/S awarded EuroHedge’s Best Global Equity Fund with Assets Below $500m
Since inception in June 2009, the Fund has had annualised returns of +26%
The Rhenman Healthcare Equity L/S, which invests in listed companies primarily in pharmaceuticals, medical technology, biotechnology and services, was awarded Best Global Equity Fund with assets below $500m at the Annual Eurohedge Awards 2014 held to celebrate fund excellence in the European hedge fund industry.
”We are very pleased to have been awarded the Best Global Equity Fund under $500m. The team works incredibly hard and it is always enjoyable to have that recognised. The healthcare sector makes up more than 10% of the total global equity market capitalisation and gives the fund many opportunities to choose from,” said Carl Grevelius, Founding Partner and Head of Marketing. The Fund managed to out-perform in 2014 whilst assets nearly doubled to MEUR 340. “We are planning to close the fund to new investors at around the MEUR 500 mark,” said Grevelius, ‘we expect to achieve that soon, as we have now filled approximately 84% of the soft close capacity, and will continue to focus on strong performance, as always.”
The fund has had consistently excellent performance, having been nominated also last year. Since inception in June 2009 the fund has returned +252% net of fees, whilst 2014 returned +43% and 2013 returned +55%. In comparison the EuroHedge Global Equity Index (in Euros) returned +66%, +3% and +11% respectively. EuroHedge said on its website, ”Henrik Rhenman's Rhenman Healthcare Equity L/S won by some distance the award for funds with assets below $500m after another sparkling year of performance.”
For more information, please contact:
Carl Grevelius, Head of Sales & Marketing / Founding Partner
Phone: +46 8 459 88 83
About Rhenman & Partners
Rhenman & Partners Asset Management is a Stockholm-based Fund Manager focusing on the healthcare sector. The company's assets under management amount to over $480m. Rhenman & Partners was founded in 2008 by a group of individuals with extensive experience of the asset management sector, as well as an unrivalled track record in the healthcare sector. Henrik Rhenman has over 20 years experience of managing successful healthcare funds.
The Rhenman Healthcare Equity L/S fund is unique in that it is supported by a Scientific Advisory Board composed of eminent professors, each with over 30 years in their field. The Group has access to a wide network of scientists and experts at several recognized institutions worldwide, including the Karolinska Institute.
The fund has a long term investment horizon and a diversified portfolio of around 60-80 core positions. Whilst trading around positions the fund remains diversified across subsectors, company size and geographies to lower volatility.
For more information, please visit www.rhepa.com
Rhenman Healthcare Equity L/S – Performance (EUR, Net of fees) –
Outstanding performance in a complex market.